Chinese positioning: 百替生物是一家 AI for Science 医学研究技术服务公司,聚焦体内细胞治疗(in vivo CAR-T/M)与核酸递送技术。
| tpLNP | A proprietary targeted lipid nanoparticle delivery platform designed to deliver nucleic acid payloads such as CAR-encoding mRNA to specific immune cells. |
|---|---|
| LINCMECAR | An in vivo CAR-T/M technology system built on the tpLNP platform, targeting refractory and relapsed diseases including oncology, fibrosis and autoimmune conditions. |
| Nanodelivery / LNP | Development of nucleic acid delivery materials and LNP formulations, including publicly disclosed patented directions such as hyperbranched poly(beta-amino ester) carriers and thermo-responsive polymers. |
Baiti Biotech has been recognized as a National High-Tech Enterprise. Multiple core invention patents have been published (publication status is distinguished from grant status). Clinical studies have been registered internationally on ClinicalTrials.gov (e.g. NCT07523555, NCT07523542); please refer to the registry for authoritative details.
Baiti Biotech is the company within the Pooling Medicine system focused on in vivo cell therapy and nucleic acid delivery technology services. The two are separate legal entities with independently stated positioning and qualifications. Pooling Medicine is an AI for Science medical research collaboration organization: its five service lines.